

Div Gupta

Partner



dgupta@cooley.com

Capital Markets

+1 212 479 6474

Life Sciences
Technology

New York

Div represents public and private emerging growth companies and investment banks on a variety of significant business transactions, including public offerings of equity and debt, crossover financings, and mergers and acquisitions. Notably, he provides strategic advice to the market's most innovative healthcare and life sciences companies on a range of issues, including general corporate and business strategy, public and private financing, and general securities matters. Div is a market leader for equity offerings and has advised on more initial public offerings (IPOs) than any other lawyer in the country since 2014, both in the healthcare and life sciences industry and generally (Deal Point Data, excluding SPAC IPOs). His counsel helps his clients raise the capital they need to develop life-saving medicines and improve human health.

In addition to representing market-leading companies, Div also represents all of the top investment banks, including BofA Securities, Barclays, BMO, Canaccord Genuity, Cantor, TD Cowen, Citigroup, Goldman Sachs, Jefferies, JMP Securities, J.P. Morgan, SVB Leerink, Morgan Stanley, Needham, Nomura, Oppenheimer, Piper Sandler, RBC, Stifel Nicolaus, UBS Securities, Wedbush, Wells Fargo and William Blair.

Div is nationally recognized for his work in capital markets, life sciences and healthcare by Chambers USA and The Legal 500 US. Who's Who Legal has also recognized him as a top life sciences lawyer. Clients describe him as "an excellent attorney with an extremely strong grasp of the law" and "collaborative, helpful and productive," also noting that he is "very solutions-oriented" and "a pleasure to work with."

Div's representative transactions include representing:

- Immunocore in its \$273 million IPO and listing on Nasdaq
- Orphazyme in its \$83.8 million IPO
- Taysha Gene Therapies in its \$181 million IPO
- Inventiva in its \$108 million IPO
- Repare Therapeutics in its \$253 million IPO
- Legend Biotech in its \$487.3 million IPO
- Gamida Cell in its \$69 million follow-on offering
- Oyster Point Pharma in its \$105 million follow-on offering
- Prevail Therapeutics in its \$125 million IPO
- Milestone Pharmaceuticals in its \$94.9 million IPO
- Gamida Cell in its \$53.2 million IPO

- Neuronetics in its \$107.5 million IPO
- ObsEva in its \$73.1 million follow-on offering
- Verrica Pharmaceuticals in its \$86.3 million IPO
- AveXis in its \$460 million follow-on offering
- ERYTECH Pharma in its \$143.7 million IPO
- Nightstar Therapeutics in its \$86 million IPO
- Dova Pharmaceuticals in its \$75.1 million IPO
- Ovid Therapeutics in its \$75 million IPO
- Biohaven in its \$193.5 million IPO
- ObsEva in its \$96.8 million IPO
- AveXis in its \$105 million IPO
- Axovant Sciences in its \$362.3 million IPO
- Bellicum Pharmaceuticals in its \$160.6 million IPO
- The underwriters in the \$250 million follow-on public offering by SpringWorks Therapeutics
- The underwriters in the \$204 million follow-on public offering by ADC Therapeutics
- The underwriters in the \$267.7 million IPO by Dyne Therapeutics
- The underwriters in the \$379.5 million follow-on public offering by Schrodinger
- The underwriters in the \$144.4 million follow-on public offering by Zentaris Pharmaceuticals
- The underwriters in the \$201.1 million IPO by iTeos Therapeutics
- The underwriters in the \$83.8 million follow-on offering by 89bio
- The underwriters in the \$690 million follow-on offering by Ascendis Pharma
- The underwriters in the \$275.1 million follow-on offering by Translate Bio
- The underwriters in the \$244.4 million IPO by Akouos
- The underwriters in the \$298.1 million IPO by Avidity Biosciences
- The underwriters in the \$90 million IPO by Calliditas Therapeutics
- The underwriters in the \$862.5 million follow-on offering by argenx
- The underwriters in the \$232.7 million IPO by ADC Therapeutics
- The underwriters in the \$190 million IPO by Zentaris Pharmaceuticals
- The underwriters in the \$75.2 million IPO by Imara
- The underwriters in the \$216 million IPO by Passage Bio
- The underwriters in the \$232.3 million IPO by Schrodinger
- The underwriters in the \$404.2 million follow-on offering by Apellis Pharmaceuticals
- The underwriters in the \$505 million follow-on offering by Reata Pharmaceuticals
- The underwriters in the \$97.6 million IPO by 89bio
- The underwriters in the \$556.6 million follow-on offering by argenx
- The underwriters in the \$186.3 million IPO by Springworks Therapeutics
- The underwriters in the \$102.6 million IPO by Karuna Therapeutics

- The underwriters in the \$103.5 million IPO by Morphic Therapeutic
- The underwriters in the \$86.3 million IPO by NextCure
- The underwriters in the \$150 million IPO by Apellis Pharmaceuticals

Div serves on the board of advisers of Life Science Cares New York, an organization that activates the financial and human capital of the life sciences industry and partners with nonprofits to disrupt the cycle of poverty and inequality in our communities, as well as on the board of trustees of Oliver Scholars, an organization that prepares high-achieving Black and Latinx students from underserved New York City communities for success at top independent schools and prestigious colleges.

Education

Harvard Law School

JD, cum laude, 2000

Yale University

BS, magna cum laude, Phi Beta Kappa, 1997

Admissions & Credentials

California

New York

Texas

Rankings & Accolades

Chambers USA: Life Sciences: Corporate/Commercial – Nationwide (2022 – 2025)

Chambers USA: Capital Markets: Debt & Equity: Eastern United States – Nationwide (2020 – 2025)

The Legal 500 US: Leading Lawyer in Capital Markets: Equity Offerings (2025)

The Legal 500 US: Key Lawyer - Capital Markets: Equity Offerings and Healthcare: Life Sciences (2020 – 2021)

Law 360 Rising Star (2015)

Who's Who Legal: Life Sciences (2018)